secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEMAITRE VASCULAR INC (LMAT)
CIK:        0001158895
Form:       8-K
Filed at:   2021-09-01T23:59:59+00:00
Accession:  0001437749-21-021311
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LeMaitre Vascular assumes EU MDR CE Mark responsibility for CardioCel/VascuCel; costs deducted from $2M earn-out
--------------------------------------------------------------------------------

- On August 28, 2021, LeMaitre amended its 2019 asset purchase agreement with Anteris Technologies (formerly Admedus).
- LeMaitre will seek CE Mark certification under EU MDR for CardioCel and VascuCel biologic patches.
- Costs of obtaining CE Mark approvals will be deducted from the $2 million earn-out payable to Anteris.
- 75% of earn-out paid after CardioCel MDR certification; 25% after VascuCel MDR certification.
- Transition services agreement extended by nine months to July 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1158895/000143774921021311/0001437749-21-021311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1158895/000143774921021311/lmat20210831_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-021311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer